EVO

Business Context and Reporting Period

Company: Evotec SE (Evotec AG)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Nine months ended September 30, 2010 (Third Quarter)
Business Overview: Evotec is a biopharmaceutical company focused on drug discovery alliances and proprietary research programs. The period was marked by the completion of the acquisition of DeveloGen AG (effective September 3, 2010), which expanded capabilities in metabolic and endocrine disorders. The company operates under the "Action Plan 2012" to focus on core programs and reduce costs.

Key Financial Metrics

Note: Operating income for 2009 included €6.6 million in impairment charges and €4.7 million in restructuring expenses. Adjusted operating income (excluding these items) for the first nine months of 2010 was €1.0 million.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 33% year-over-year for both the nine-month period and Q3, driven by strong performance in drug discovery alliances and milestone achievements (notably €2.5 million from Boehringer Ingelheim).
• Profitability Turnaround: The company moved from a significant operating loss in 2009 to a positive operating result in 2010. This was achieved through a 79% reduction in R&D expenses and a 12% reduction in SG&A costs.
• Acquisition Impact: The acquisition of DeveloGen added €167,000 in revenue and a net loss of €112,000 for the period. It also increased intangible assets and goodwill significantly.
• Cost Structure: R&D expenses dropped dramatically due to the closure of the US site, reduction of early discovery programs, and successful partnering (e.g., Roche funding EVT 100 series).

Guidance, Outlook, and Risks

Financial Guidance (2010)

• Revenue: Confirmed guidance of €52–54 million (growth >20%). Supported by an order book of €51 million as of October 2010.
• R&D Expenses: Revised downward to approximately €8 million (from €10 million) due to successful partnering.
• Liquidity: Year-end liquidity target confirmed at >€64 million, despite ~€2 million cash outflow for the DeveloGen acquisition.

Outlook (2011 and Beyond)

• Revenue growth of >15% expected for 2011.
• Target to reach sustainable profitability by 2012 at the latest.

Key Developments and Risks

• Partnerships: New alliances initiated with Almirall (ion channels), Shionogi (fragment-based discovery), and Apeiron Biologics (pain). Milestone achieved with Boehringer Ingelheim.
• Clinical Progress: Phase II trial for EVT 101 (treatment-resistant depression) with Roche is on track. License agreement signed with Jingxin Pharma for EVT 201 (insomnia) in China.
• Risks: Forward-looking statements are subject to risks including clinical trial failures, inability to secure regulatory approval, competition, and the success of collaborations. The company notes that gross margins may remain volatile due to milestone payments.

Investor Verification Checklist

• DeveloGen Integration: Verify the realization of synergies and the impact of the €23.7 million purchase price (including earn-out provisions) on future cash flows.
• Roche Partnership: Monitor the progress of the EVT 101 Phase II trial, as a successful buy-back option could yield a $65 million lump sum plus milestones.
• Order Book Conversion: Confirm that the €51 million order book translates into recognized revenue in 2010 and 2011 as guided.
• Liquidity Management: Track cash burn rates and the ability to maintain >€64 million liquidity through year-end, considering the DeveloGen cash requirements.
• Non-GAAP Reconciliation: Review the reconciliation between IFRS operating income and adjusted operating income to understand the impact of one-time charges in prior periods versus current operational efficiency.